Cargando…
Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”
Autor principal: | Mantelli, Flavio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684829/ https://www.ncbi.nlm.nih.gov/pubmed/36417164 http://dx.doi.org/10.1007/s40121-022-00727-4 |
Ejemplares similares
-
Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
por: Ito, Shun, et al.
Publicado: (2022) -
A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
por: Landoni, Giovanni, et al.
Publicado: (2022) -
Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study
por: Piemonti, Lorenzo, et al.
Publicado: (2023) -
Letter to the Editor Regarding Efficacy and Safety of Diclofenac and Capsaicin Gel in Patients with Acute Back/Neck Pain: A Multicenter Randomized Controlled Study
por: Schwartz, Ruben, et al.
Publicado: (2020) -
Author’s Response to: ‘Letter to the Editor Regarding Efficacy and Safety of Diclofenac and Capsaicin Gel in Patients with Acute Back/Neck Pain: A Multicenter Randomized Controlled Study’
por: Weiser, Thomas W., et al.
Publicado: (2020)